
IDEAYA Biosciences, Inc.
- Jurisdiction
United States - LEI
549300ULW08F62IJML11 - ISIN
US45166A1025 (IDYA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Read full profile
Fundamentals
- Net revenue
€5.97M - Gross margin
90.8% - EBIT
-€327.73M - EBIT margin
-5,488.9% - Net income
-€282.35M - Net margin
-4,729.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: March 15, 2022 (Q4 2021)